Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retina diseases, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Russell Trenary, President and CEO, will engage in a fireside chat during the event.
The video webcast of the fireside chat will be available on-demand starting at 7:00 AM ET on August 15 for registered attendees. It will also be accessible on the company's website in the Investors section's Events page. The webcast replay will remain archived for 90 days after the event.
Outlook Therapeutics (Nasdaq: OTLK), un'azienda biofarmaceutica che sviluppa ONS-5010/LYTENAVA™ (bevacizumab-vikg) per le malattie retiniche, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale di Oftalmologia Annuale H.C. Wainwright che si terrà il 15 agosto 2024. Russell Trenary, Presidente e CEO, parteciperà a una chiacchierata informale durante l'evento.
La registrazione video della chiacchierata sarà disponibile on-demand a partire dalle 7:00 AM ET del 15 agosto per i partecipanti registrati. Sarà inoltre accessibile sul sito web dell'azienda nella sezione Eventi della pagina Investitori. La registrazione sarà archiviata per 90 giorni dopo l'evento.
Outlook Therapeutics (Nasdaq: OTLK), una empresa biofarmacéutica que desarrolla ONS-5010/LYTENAVA™ (bevacizumab-vikg) para enfermedades de la retina, anunció su participación en la 4ª Conferencia Virtual Anual de Oftalmología de H.C. Wainwright que se llevará a cabo el 15 de agosto de 2024. Russell Trenary, Presidente y CEO, participará en una charla informal durante el evento.
La transmisión en video de la charla estará disponible bajo demanda a partir de las 7:00 AM ET del 15 de agosto para los asistentes registrados. También estará accesible en el sitio web de la empresa en la página de Eventos de la sección Inversores. La repetición de la transmisión se archivará durante 90 días después del evento.
Outlook Therapeutics (Nasdaq: OTLK)는 망막 질환을 위한 ONS-5010/LYTENAVA™ (bevacizumab-vikg)를 개발하는 생명공학 회사로, 2024년 8월 15일에 H.C. Wainwright 제4회 연례 안과 가상 콘퍼런스에 참여한다고 발표했습니다. Russell Trenary 사장 겸 CEO는 행사 중 화상 대담에 참여할 예정입니다.
화상 대담의 비디오 웹캐스트는 2024년 8월 15일 오전 7:00 ET부터 등록된 참석자가 온디맨드로 이용할 수 있습니다. 또한 회사 웹사이트의 투자자 섹션 이벤트 페이지에서도 액세스할 수 있습니다. 웹캐스트 리플레이는 행사 후 90일 동안 보관됩니다.
Outlook Therapeutics (Nasdaq: OTLK), une entreprise biopharmaceutique développant ONS-5010/LYTENAVA™ (bevacizumab-vikg) pour les maladies de la rétine, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright qui se tiendra le 15 août 2024. Russell Trenary, Président et CEO, participera à une discussion informelle lors de l'événement.
La retransmission vidéo de la discussion sera disponible à la demande à partir de 7h00 ET le 15 août pour les participants enregistrés. Elle sera également accessible sur le site web de l'entreprise dans la page événements de la section investisseurs. La rediffusion restera archivée pendant 90 jours après l'événement.
Outlook Therapeutics (Nasdaq: OTLK), ein biopharmazeutisches Unternehmen, das ONS-5010/LYTENAVA™ (bevacizumab-vikg) für Netzhauterkrankungen entwickelt, gab seine Teilnahme an der 4. Virtuellen Augenheilkunde-Konferenz von H.C. Wainwright am 15. August 2024 bekannt. Russell Trenary, Präsident und CEO, wird während der Veranstaltung an einem informellen Gespräch teilnehmen.
Die Videoübertragung des Gesprächs wird ab 15. August um 7:00 Uhr ET für registrierte Teilnehmer auf Abruf verfügbar sein. Sie wird außerdem auf der Website des Unternehmens im Abschnitt 'Investoren' auf der Veranstaltungsseite zugänglich sein. Die Wiederholung der Übertragung wird 90 Tage nach der Veranstaltung archiviert.
- None.
- None.
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference being held on Thursday, August 15, 2024.
A video webcast of the fireside chat will be accessible for viewing on-demand beginning on Thursday, August 15, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.
For more information about the conference, please visit the conference website.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and United Kingdom Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD in the first calendar quarter of 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA application to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. For more information, please visit www.outlooktherapeutics.com.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the H.C. Wainwright Ophthalmology Conference?
Who will be representing Outlook Therapeutics (OTLK) at the conference?
How can investors access Outlook Therapeutics' (OTLK) presentation at the conference?
What product is Outlook Therapeutics (OTLK) developing?
How long will the webcast of Outlook Therapeutics' (OTLK) presentation be available?
